Throughout this winter season our editorial team has brought you timely, evidence-based coverage that spanned clinical research, practice challenges, expert insights, and interactive learning. In this...
This year we’ve explored critical clinical insights, cutting-edge care strategies, and expert perspectives on our podcast. Today, we’re excited to count down the five standout podcast episodes that...
A recent meta-analysis demonstrated that adherence to this dietary pattern is associated with an 11–30% reduction in the risk of cognitive impairment, dementia, and Alzheimer disease. This quiz will...
With the approval of the first anti-amyloid antibodies, lecanemab and donanemab, the therapeutic landscape for Alzheimer disease has entered a new era—one that presents both promise and complexity. This...
In an interview with Consultant360, Paul B. Rosenberg, MD, discussed his team’s research on using dronabinol, a legal form of synthetic THC, to treat agitation in patients with Alzheimer disease. What...
In an interview with Consultant360, Kasia Rothenberg, MD, PhD, a geriatric psychiatrist at the Cleveland Clinic Lou Ruvo Center for Brain Health, described the challenges caregivers or family members face...
